Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. [PDF]
, 2016 Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood.
Fang, Li Tai +11 more
core +3 more sources
Malignant pleural mesothelioma: an update [PDF]
Jornal Brasileiro de Pneumologia, 2021 Malignant mesotheliomas are rare types of cancers that affect the mesothelial surfaces, usually the pleura and peritoneum. They are associated with asbestos exposure, but due to a latency period of more than 30 years and difficult diagnosis, most cases are not detected until they reach advanced stages.
Hajj, Glaucia N. M. +5 more
openaire +5 more sources
Malignant pleural mesothelioma
Annals of Oncology, 2006 Malignant pleural mesothelioma G. L. Ceresoli, G. P. Betta, B. Castagneto, F. Facciolo, G. Arcangeli, P. A. Zucali, R. Libener, D. De Giovanni, E. Melis & M. A. Mirri Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano (MI); Pathology Unit, Department of Oncology, Azienda Sanitaria Ospedaliera, Alessandria ...
G L, Ceresoli +9 more
openaire +2 more sources
Orphanet Journal of Rare Diseases, 2008 Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
Parker Robert J +2 more
doaj +1 more source
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. [PDF]
, 2015 Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to control. Despite some benefit from using the multimodality-approach (surgery, combination chemotherapy and radiation), survival remains poor. However, current research produced a
Cameron, Robert B +2 more
core +2 more sources
In Vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma [PDF]
, 2017 Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor. The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a "multifunctional drug". Several studies have demonstrated API anti-tumoral effects.
Andrea Modesti +13 more
core +2 more sources
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]
, 2011 BackgroundTumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro.
Broaddus, V Courtney +8 more
core +3 more sources
Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening [PDF]
, 2017 Introduction: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a programme could maximise access
Blyth, Kevin G. +2 more
core +1 more source
A comparison of the results from intra-pleural and intra-peritoneal studies with those from inhalation and intratracheal tests for the assessment of pulmonary responses to inhalable dusts and fibres. [PDF]
, 2016 The aim of this paper is to compare results from inhalation studies with those from intraperitoneal and intrapleural tests, where available, for a number of fibrous and particulate test materials.
Bevan, Ruth +2 more
core +2 more sources
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]
, 2018 SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L. +11 more
core +2 more sources